DexCom earnings beat by $0.03, revenue topped estimates
Investing.com -- Nyxoah SA (BR:NYXH) (NASDAQ:NYXH) stock climbed 8.8% following the publication of its DREAM pivotal study data in the Journal of Clinical Sleep Medicine, which revealed strong patient usage rates and satisfaction with the company’s Genio system for treating obstructive sleep apnea.
The peer-reviewed publication showed that 84.3% of participants used the device for more than 4 hours in over 70% of nights during the 3 months preceding the 12-month visit. Additionally, 85.9% of participants used the device on more than 70% of nights, with 90% expressing satisfaction with the therapy.
The study, which supported Nyxoah’s PMA submission to the FDA, achieved its co-primary endpoints with a 63.5% AHI responder rate and 71.3% ODI responder rate at 12 months. The data also revealed a reduction in patients’ snoring scores from 83.5% at baseline to 30.4% at 12 months.
"The DREAM study demonstrated efficacy of bilateral hypoglossal nerve stimulation using Genio for the treatment of obstructive sleep apnea," said B. Tucker Woodson, MD, Professor at Medical (TASE:BLWV) College of Wisconsin and Principal Investigator of the study. "Genio demonstrated a strong effect in reducing disease burden and improving quality of life by significantly reducing the apnea hypopnea burden encouraging patient adherence and satisfaction."
The safety profile was comparable to other neuromodulation therapies, with an 8.7% serious adverse event rate. The study also showed a 66.6% median reduction in supine AHI at 12 months compared to baseline, along with significant improvements in quality-of-life outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.